Drug delivery coating for use with a stent

• US 8,722,077 B2
• Filed: 08/24/2012
• Issued: 05/13/2014
• Est. Priority Date: 09/28/2004
• Status: Expired due to Fees

• Current Assignee: Atrium Medical Corporation (Getinge AB)
• Original Assignee: Atrium Medical Corporation (Getinge AB)
• Inventors: Labrecque, Roger, Moodie, Geoffrey, Ferraro, Joseph, Rogers, Lisa, Martakos, Paul, Karwoski, Theodore, Herweck, Steve A.
• Primary Examiner(s): Long, Scott
• Assistant Examiner(s): BECKHARDT, LYNDSEY MARIE
• Application Number:
  US13/593,656
• Publication Number:
  US 20120315219A1
• Time in Patent Office: 627 Days
• Field of Search: None
• US Class Current: 424/423
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2/86 Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/22 Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• CPC Class Codes: A61K 47/44 Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14
• CPC Class Codes: A61L 2300/22 Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/428 Vitamins, e.g. tocopherol, riboflavin
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 2420/02 Methods for coating medical devices
• CPC Class Codes: A61L 31/08 Materials for coatings
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61M 25/0009 Making of catheters or other medical or surgical tubes
• CPC Class Codes: A61M 25/0045 multi-layered, e.g. coated coating materials A61L29/08
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 : Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

A coated medical device and a method of providing a coating on an implantable medical device result in a medical device having a bio-absorbable coating. The coating includes a bio-absorbable carrier component. In addition to the bio-absorbable carrier component, a therapeutic agent component can also be provided. The coated medical device is implantable in a patient to effect controlled delivery of the coating, including the therapeutic agent, to the patient.

Claims

1. A coated medical device, comprising:

the medical device; and

a coating disposed on the medical device, the coating comprising;

a bio-absorbable cross-linked material;

a cellular uptake inhibitor; and

a therapeutic agent;

wherein the bio-absorbable cross-linked material comprises two or more omega-3 fatty acids cross-linked into a substantially random configuration by ester bonds.

2. The device of claim 1, wherein the cellular uptake inhibitor comprises alpha-tocopherol.

3. The device of claim 1, wherein the two or more omega-3 fatty acids comprise eicosapentaenoic acid (EPA).

4. The device of claim 1, wherein the two or more omega-3 fatty acids comprise docosahexaenoic acid (DHA).

5. The device of claim 1, wherein the two or more omega-3 fatty acids comprise α

-linolenic acid (ALA).

6. The device of claim 1, wherein the bio-absorbable cross-linked material is derived from a naturally occurring oil, an oil composition, or both.

7. The device of claim 1, wherein the bio-absorbable cross-linked material is derived from fish oil.

8. The device of claim 1, wherein the therapeutic agent comprises one or more agents selected from the group of agents consisting of antioxidants, anti-inflammatory agents, anti-coagulant agents, drugs to alter lipid metabolism, anti-proliferatives, anti-neoplastics, anti-fibrotics, immunosuppressive, tissue growth stimulants, functional protein/factor delivery agents, anti-infective agents, imaging agents, anesthetic agents, chemotherapeutic agents, tissue absorption enhancers, anti-adhesion agents, germicides, antiseptics, proteoglycans, GAG'"'"'s, polynucleotides, analgesics, prodrugs, or polysaccharides.

9. The device of claim 1, wherein the therapeutic agent component comprises one or more agents selected from the group of agents consisting of cerivastatin, cilostazol, fluvastatin, lovastatin, paclitaxel, pravastatin, rapamycin, or simvastatin.

10. The device of claim 1, wherein the medical device comprises a stent.

11. The device of claim 10, wherein the stent is formed of one or more substance selected from the group of substances consisting of stainless steel, Nitinol alloy, nickel alloy, titanium alloy, cobalt-chromium alloy, ceramics, metals, plastics, or polymers.

12. The device of claim 1, further comprising a pre-treatment provided between the medical device and the coating comprising omega-3 fatty acids, wherein the pre-treatment improves consistency and conformability and enhances the adhesion of the coating comprising the bio-absorbable carrier component.

13. The device of claim 12, wherein the pre-treatment is bio-absorbable.

14. The device of claim 12, wherein the pre-treatment comprises a naturally occurring oil, an oil composition, or both.

15. The device of claim 12, wherein the pre-treatment comprises fish oil.

16. The device of claim 12, wherein the pre-treatment is modified from its naturally occurring state to a state of increased viscosity in the form of a cross-linked material.

17. The device of claim 16, wherein the modification of the pre-treatment from its naturally occurring state to the state of increased viscosity occurs prior to application of the pre-treatment on the device.

18. A method of making a coated medical device, the method comprising:

providing the medical device; and

coating the medical device with a bio-absorbable cross-linked material, a cellular uptake inhibitor, and a therapeutic agent;

wherein the bio-absorbable cross-linked material comprises two or more omega-3 fatty acids cross-linked into a substantially random configuration by ester bonds.

19. The method of claim 18, wherein the cellular uptake inhibitor comprises alpha-tocopherol.

20. The method of claim 18, wherein the bio-absorbable cross-linked material comprises a naturally occurring oil, an oil composition, or a combination of both, that have undergone at least partial curing in an amount sufficient to form the substantially random configuration of cross-linked ester bonds.

21. The method of claim 18, wherein the omega-3 fatty acids are supplied from fish oil.

22. The method of claim 18, wherein bonds of the substantially random configuration of ester bonds forming the cross-linked fatty acids are formed prior to the step of coating the medical device.

23. The method of claim 18, wherein the step of coating comprises applying omega-3 fatty acids to the medical device and curing the omega-3 fatty acids to form substantially random configuration of ester bonds forming the cross-linked fatty acids.

24. The method of claim 18, wherein the therapeutic agent component comprises one or more agents selected from the group of agents consisting of antioxidants, anti-inflammatory agents, anti-coagulant agents, drugs to alter lipid metabolism, anti-proliferatives, anti-neoplastics, anti-fibrotics, immunosuppressives, tissue growth stimulants, functional protein/factor delivery agents, anti-infective agents, imaging agents, anesthetic agents, chemotherapeutic agents, tissue absorption enhancers, anti-adhesion agents, germicides, antiseptics, proteoglycans, GAG'"'"'s, polynucleotides, analgesics, prodrugs, or polysaccharides (heparin).

25. The method of claim 18, wherein the therapeutic agent component comprises one or more agents selected from the group of agents consisting of cerivastatin, cilostazol, fluvastatin, lovastatin, paclitaxel, pravastatin, rapamycin, or simvastatin.

26. The method of claim 18, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA).

27. The method of claim 18, wherein the medical device comprises a stent.

28. The method of claim 27, wherein the stent is formed of one or more substances selected from the group of substances consisting of stainless steel, Nitinol alloy, nickel alloy, titanium alloy, cobalt-chromium alloy, ceramics, metals, plastics, or polymers.

29. The method of claim 18, further comprising providing a pre-treatment between the medical device and the coating comprising omega-3 fatty acids, wherein the pre-treatment improves consistency and conformability and enhances the adhesion of the coating comprising the bio-absorbable carrier component.

30. The method of claim 29, wherein the pre-treatment is bio-absorbable.

31. The method of claim 29, wherein the pre-treatment comprises a naturally occurring oil, an oil composition, or both.

32. The method of claim 29, wherein the pre-treatment comprises fish oil.

33. The method of claim 29, further comprising modifying the pre-treatment from its naturally occurring state to a state of increased viscosity in the form of a cross-linked material.

34. The method of claim 18, further comprising forming the bio-absorbable cross-linked material by curing while on the medical device.

35. The method of claim 34, wherein curing comprises applying at least one curing method selected from a group of curing methods comprised of heat or UV light.

36. A coated medical device, comprising:

a pre-treatment provided on the medical device having a first bio-absorbable cross-linked material; and

a coating disposed on top of the pre-treatment, the coating having a second bio-absorbable cross-linked material, a cellular uptake inhibitor, a therapeutic agent;

wherein the pre-treatment improves consistency and conformability and enhances the adhesion of the coating to the medical device;

wherein the coated medical device is implantable in a patient to effect controlled delivery of the therapeutic agent to the patient;

wherein the controlled delivery is at least partially characterized by total and relative amounts of the cellular uptake inhibitor and bio-absorbable cross-linked material; and

wherein the bio-absorbable cross-linked material comprises two or more omega-3 fatty acids cross-linked into a substantially random configuration by ester bonds.

37. The device of claim 36, wherein the cellular uptake inhibitor comprises alpha-tocopherol.

38. The device of claim 36, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA).

39. The device of claim 36, wherein the medical device comprises a stent.